TuHURA Biosciences (HURA)

• Market cap: $57.6M
• 1 day: -1.92%
• 5 days: -47.69%
• 1 month: -54.26%
• 3 months: -59.2%
• 6 months: -61.07%
• Year to date: -75.18%
• 1 year: -81.04%
• 5 years: -99.96%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Employees: 19